BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29125981)

  • 1. The clinical development of vaccines for HER2
    Costa RLB; Soliman H; Czerniecki BJ
    Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
    Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
    Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-Based Immunotherapy for Breast Cancer.
    Cui N; Shi J; Yang C
    Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
    Arab A; Yazdian-Robati R; Behravan J
    Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
    Milani A; Sangiolo D; Montemurro F; Aglietta M; Valabrega G
    Ann Oncol; 2013 Jul; 24(7):1740-1748. PubMed ID: 23585514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing anti-HER2 vaccines: Breast cancer experience.
    Al-Awadhi A; Lee Murray J; Ibrahim NK
    Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Memory CD8
    Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
    Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.
    Nocera NF; Lee MC; Czerniecki BJ
    Future Oncol; 2017 Jul; 13(17):1459-1462. PubMed ID: 28766964
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?
    Armstrong AC; Gilham DE
    Breast Cancer Res; 2012 May; 14(3):106. PubMed ID: 22643384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER2 vaccines: new prospects for breast cancer therapy.
    Ladjemi MZ; Jacot W; Chardès T; Pèlegrin A; Navarro-Teulon I
    Cancer Immunol Immunother; 2010 Sep; 59(9):1295-312. PubMed ID: 20532501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Breast Cancer.
    Marmé F
    Oncol Res Treat; 2016; 39(6):335-45. PubMed ID: 27260697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
    De La Cruz LM; Nocera NF; Czerniecki BJ
    Immunotherapy; 2016 Oct; 8(10):1219-32. PubMed ID: 27605070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
    Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
    Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.
    Orlandi F; Guevara-Patiño JA; Merghoub T; Wolchok JD; Houghton AN; Gregor PD
    Vaccine; 2011 May; 29(20):3646-54. PubMed ID: 21435405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
    Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W
    Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast Cancer Vaccines: Disappointing or Promising?
    Zhu SY; Yu KD
    Front Immunol; 2022; 13():828386. PubMed ID: 35154149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
    Jackson DO; Trappey FA; Clifton GT; Vreeland TJ; Peace KM; Hale DF; Litton JK; Murray JL; Perez SA; Papamichail M; Mittendorf EA; Peoples GE
    Clin Immunol; 2018 Oct; 195():28-35. PubMed ID: 30025819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.